230 related articles for article (PubMed ID: 34533608)
1. Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis.
Craft S; Ferris JA; Barratt MJ; Maier LJ; Lynskey MT; Winstock AR; Freeman TP
Psychopharmacology (Berl); 2022 May; 239(5):1349-1357. PubMed ID: 34533608
[TBL] [Abstract][Full Text] [Related]
2. Does cannabis testing in the military drive synthetic cannabinoid use? Self-reported use motivations among justice-involved veterans.
Santangelo O; Baldwin JM; Stogner J
Int J Drug Policy; 2022 Aug; 106():103756. PubMed ID: 35738030
[TBL] [Abstract][Full Text] [Related]
3. [Intoxications with synthetic cannabinoids].
Zanen JG; Leegwater E; Schippers EF; Wilms EB
Ned Tijdschr Geneeskd; 2023 Mar; 167():. PubMed ID: 36943159
[TBL] [Abstract][Full Text] [Related]
4. [Intoxications with synthetic cannabinoids].
Zanen JG; Leegwater E; Schippers EF; Wilms EB
Ned Tijdschr Geneeskd; 2023 Feb; 166():. PubMed ID: 36752668
[TBL] [Abstract][Full Text] [Related]
5. Activity-based detection of synthetic cannabinoid receptor agonists in plant materials.
Timmerman A; Balcaen M; Coopman V; Degreef M; Pottie E; Stove CP
Harm Reduct J; 2024 Jul; 21(1):127. PubMed ID: 38951904
[TBL] [Abstract][Full Text] [Related]
6. The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients.
Jackson MA; Brown AL; Johnston J; Clancy R; McGregor I; Bruno R; Lintzeris N; Montebello M; Luksza J; Bowman J; Phung N; Allsop D; Dunlop AJ
J Cannabis Res; 2021 Jul; 3(1):33. PubMed ID: 34311790
[TBL] [Abstract][Full Text] [Related]
7. Cannabimimetic effects of abused indazole-carboxamide synthetic cannabinoid receptor agonists AB-PINACA, 5F-AB-PINACA and 5F-ADB-PINACA in mice: Tolerance, dependence and withdrawal.
Wilson CD; Hiranita T; Fantegrossi WE
Drug Alcohol Depend; 2022 Jul; 236():109468. PubMed ID: 35643039
[TBL] [Abstract][Full Text] [Related]
8. Characterizing Trends in Synthetic Cannabinoid Receptor Agonist Use from Patient Clinical Evaluations during Medical Toxicology Consultation.
Tebo C; Mazer-Amirshahi M; Wax P; Campleman S; Boyer E; Brent J; Sheth A; Daniuaityte R; Carlson R
J Psychoactive Drugs; 2021; 53(3):207-214. PubMed ID: 33225872
[TBL] [Abstract][Full Text] [Related]
9. Adding more "spice" to the pot: A review of the chemistry and pharmacology of newly emerging heterocyclic synthetic cannabinoid receptor agonists.
Alam RM; Keating JJ
Drug Test Anal; 2020 Mar; 12(3):297-315. PubMed ID: 31854124
[TBL] [Abstract][Full Text] [Related]
10. Clinical Effects of Synthetic Cannabinoid Receptor Agonists Compared with Marijuana in Emergency Department Patients with Acute Drug Overdose.
Zaurova M; Hoffman RS; Vlahov D; Manini AF
J Med Toxicol; 2016 Dec; 12(4):335-340. PubMed ID: 27255136
[TBL] [Abstract][Full Text] [Related]
11. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects.
van Amsterdam J; Brunt T; van den Brink W
J Psychopharmacol; 2015 Mar; 29(3):254-63. PubMed ID: 25586398
[TBL] [Abstract][Full Text] [Related]
12. Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists.
Patel M; Manning JJ; Finlay DB; Javitch JA; Banister SD; Grimsey NL; Glass M
Biochem Pharmacol; 2020 May; 175():113871. PubMed ID: 32088263
[TBL] [Abstract][Full Text] [Related]
13. Synthetic cannabinoid use among a sample of individuals enrolled in community-based recovery programs: Are synthetic cannabinoids actually preferred to other drugs?
Smith KE; Staton M
Subst Abus; 2019; 40(2):160-169. PubMed ID: 30457960
[No Abstract] [Full Text] [Related]
14. Synthetic Cannabinoid-Related Deaths in England, 2012-2019.
Yoganathan P; Claridge H; Chester L; Englund A; Kalk NJ; Copeland CS
Cannabis Cannabinoid Res; 2022 Aug; 7(4):516-525. PubMed ID: 33998886
[No Abstract] [Full Text] [Related]
15. Assessment of Withdrawal, Mood, and Sleep Inventories After Monitored 3-Week Abstinence in Cannabis-Using Adolescents and Young Adults.
Sullivan RM; Wallace AL; Stinson EA; Montoto KV; Kaiver CM; Wade NE; Lisdahl KM
Cannabis Cannabinoid Res; 2022 Oct; 7(5):690-699. PubMed ID: 34678051
[No Abstract] [Full Text] [Related]
16. Suspected synthetic cannabinoid receptor agonist intoxication: Does analysis of samples reflect the presence of suspected agents?
Tebo C; Mazer-Amirshahi M; DeGeorge L; Gelfand B; Leak C; Tolliver S; Sauter D
Am J Emerg Med; 2019 Oct; 37(10):1846-1849. PubMed ID: 30595429
[TBL] [Abstract][Full Text] [Related]
17. 'Synthetic cannabis': A dangerous misnomer.
Darke S; Banister S; Farrell M; Duflou J; Lappin J
Int J Drug Policy; 2021 Dec; 98():103396. PubMed ID: 34343944
[TBL] [Abstract][Full Text] [Related]
18. Involuntary MDMB-4en-PINACA intoxications following cannabis consumption: clinical and analytical findings.
Goncalves R; Labadie M; Chouraqui S; Peyré A; Castaing N; Daveluy A; Molimard M
Clin Toxicol (Phila); 2022 Apr; 60(4):458-463. PubMed ID: 34850659
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom National Poisons Information Service.
Waugh J; Najafi J; Hawkins L; Hill SL; Eddleston M; Vale JA; Thompson JP; Thomas SH
Clin Toxicol (Phila); 2016 Jul; 54(6):512-8. PubMed ID: 27091041
[TBL] [Abstract][Full Text] [Related]
20. Spicing it up - synthetic cannabinoid receptor agonists and psychosis - a systematic review.
Hobbs M; Kalk NJ; Morrison PD; Stone JM
Eur Neuropsychopharmacol; 2018 Dec; 28(12):1289-1304. PubMed ID: 30454908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]